PDS Biotechnology Corp PDSB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PDSB is a good fit for your portfolio.
News
-
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
-
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
-
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
-
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Trading Information
- Previous Close Price
- $3.26
- Day Range
- $3.20–3.34
- 52-Week Range
- $2.59–10.26
- Bid/Ask
- $3.34 / $3.35
- Market Cap
- $122.51 Mil
- Volume/Avg
- 144,082 / 934,078
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.pdsbiotech.com
Comparables
Valuation
|
Metric
|
PDSB
|
CLDX
|
RCUS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.07 | 4.82 | 2.41 |
Price/Sales | — | 260.58 | 9.32 |
Price/Cash Flow | — | — | — |
Price/Earnings
PDSB
CLDX
RCUS
Financial Strength
|
Metric
|
PDSB
|
CLDX
|
RCUS
|
|---|---|---|---|
Quick Ratio | 4.15 | 13.69 | 4.35 |
Current Ratio | 4.33 | 13.87 | 4.52 |
Interest Coverage | −10.23 | — | −170.00 |
Quick Ratio
PDSB
CLDX
RCUS
Profitability
|
Metric
|
PDSB
|
CLDX
|
RCUS
|
|---|---|---|---|
Return on Assets (Normalized) | −54.59% | −30.49% | −20.42% |
Return on Equity (Normalized) | −105.82% | −33.19% | −44.44% |
Return on Invested Capital (Normalized) | −59.98% | −32.85% | −49.53% |
Return on Assets
PDSB
CLDX
RCUS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vbjhkvbnx | Fwn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Llbzcbdv | Mpbhjzx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qzvhsdlz | Trqbrj | $97.8 Bil | |
MRNA
| Moderna Inc | Svpwmncw | Rcf | $38.8 Bil | |
ARGX
| argenx SE ADR | Nkwcxhyk | Bsl | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Nsmkthknx | Nbmbj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hwxwftpq | Qkbxgjy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Spmnyxkw | Whsgzb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ntnktrbk | Rwcvrx | $12.5 Bil | |
INCY
| Incyte Corp | Kvpggsf | Wrxzh | $11.5 Bil |